HighGravityData
Companies / Biopharma / GILD

Gilead Sciences

GILD · Biopharma sector group
Guidance from Gilead Sciences’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Current guidance
19 items
Releases tracked
8
Latest release
Aug 4, 2026
Data checked
Aug 4, 2026
On this page:Latest changes·Current guidance·Your sector group·History

What changed in the Aug 4, 2026 release

Each item compared with the same item in the previous release (May 7, 2026). Values in quotation marks are the company’s words.

New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
ChangeMetricPeriodPreviousNowSource
NewGAAP projected operating income (loss) (in millions)for FY2026—“$(2,250) - $(1,850)”Filing ↗
NewNon-GAAP projected operating income (in millions)for FY2026—“$2,900 - $3,300”Filing ↗
NewDiluted loss per sharefor FY2026—“$ (3.75) $ (3.40)”Filing ↗
LoweredGAAP projected effective tax ratefor FY2026“~ 21%”“~ (80%) - (90%)”Filing ↗
NewGAAP projected effective tax rate excluding Acquired IPR&D expensesfor FY2026—“~21%”Filing ↗
NewNon-GAAP diluted loss per sharefor FY2026—“$ (0.65) $ (0.30)”Filing ↗
RaisedNon-GAAP projected effective tax ratefor FY2026“~ 20%”“~ 140% - 115%”Filing ↗
NewNon-GAAP projected effective tax rate excluding Acquired IPR&D expensesfor FY2026—“~20%”Filing ↗
NewProduct sales (in millions)for FY2026—“$ 30,100 $ 30,400”Filing ↗
NewProduct sales excluding Veklury (in millions)for FY2026—“$ 29,800 $ 30,100”Filing ↗
NewVeklury (in millions)for FY2026—“~ $300”Filing ↗
NewDiluted loss per shareNo period stated—“$ (3.75)”Filing ↗
NewNon-GAAP diluted loss per shareNo period stated—“$ (0.65)”Filing ↗
RaisedProduct salesNo period stated“$ 30,000”“$ 30,100”Filing ↗
RaisedProduct sales excluding VekluryNo period stated“$ 29,400”“$ 29,800”Filing ↗
ReiteratedGAAP projected product gross marginfor FY2026“~ 79.0%”“~ 79.0%”Filing ↗
ReiteratedNon-GAAP projected product gross marginfor FY2026“~ 87.0%”“~ 87.0%”Filing ↗

Current guidance

Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.

Current fiscal year
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Diluted EPS“$6.75 - $7.15”for FY2026GAAP-tiedFeb 10, 20261Filing ↗
GAAP projected operating income“$11,400 - $11,900”for FY2026GAAP-tiedFeb 10, 20261Filing ↗
GAAP projected operating income (loss) (in millions)“$(2,250) - $(1,850)”for FY2026GAAP-tiedAug 4, 20261Filing ↗
GAAP projected product gross margin“~ 79.0%”for FY2026GAAP-tiedFeb 10, 20262Filing ↗
Non-GAAP diluted EPS“$8.45 - $8.85”for FY2026Company-definedFeb 10, 20261Filing ↗
Non-GAAP projected operating income“$13,800 - $14,300”for FY2026Company-definedFeb 10, 20261Filing ↗
Non-GAAP projected operating income (in millions)“$2,900 - $3,300”for FY2026Company-definedAug 4, 20261Filing ↗
Non-GAAP projected product gross margin“~ 87.0%”for FY2026Company-definedFeb 10, 20262Filing ↗
Diluted loss per share“$ (3.75) $ (3.40)”for FY2026GAAP-tiedAug 4, 20261Filing ↗
GAAP projected effective tax rate“~ (80%) - (90%)”for FY2026GAAP-tiedFeb 10, 20262Filing ↗
GAAP projected effective tax rate excluding Acquired IPR&D expenses“~21%”for FY2026GAAP-tiedAug 4, 20261Filing ↗
Non-GAAP diluted loss per share“$ (0.65) $ (0.30)”for FY2026Company-definedAug 4, 20261Filing ↗
Non-GAAP projected effective tax rate“~ 140% - 115%”for FY2026Company-definedFeb 10, 20262Filing ↗
Non-GAAP projected effective tax rate excluding Acquired IPR&D expenses“~20%”for FY2026Company-definedAug 4, 20261Filing ↗
Product sales (in millions)“$ 30,100 $ 30,400”for FY2026Company-definedAug 4, 20261Filing ↗
Product sales excluding Veklury (in millions)“$ 29,800 $ 30,100”for FY2026Company-definedAug 4, 20261Filing ↗
Quarterly dividend declared“$0.82 per share”for Q3 FY2026Declared actionAug 4, 20261Filing ↗
Quarterly dividend of common stock“$0.82 per share”for Q3 FY2026Declared actionAug 4, 20261Filing ↗
Veklury (in millions)“~ $300”for FY2026Company-definedAug 4, 20261Filing ↗
Next year and medium term
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Planned investment in the U.S.“$32 billion”for FY2030Company-definedOct 30, 20251Filing ↗
Planned U.S. manufacturing and R&D investment“$32 billion”for FY2030Company-definedOct 30, 20251Filing ↗
No period stated
MetricCurrent valuePeriodMeasureFirst statedTimes statedSource
Stock repurchase program authorization“$6.0 billion”—Declared actionAug 7, 20251Filing ↗

How one item moved

Product sales, No period stated — every statement across the year, each linked to its filing.

Nov 6, 2024
New
“$ 27,800”
Filing ↗
Feb 11, 2025
Raised
“$ 28,200”
Filing ↗
Apr 24, 2025
Reiterated
“$ 28,200”
Filing ↗
Aug 7, 2025
Raised
“$ 28,300”
Filing ↗

How your Biopharma sector group guides

12 companies in Biopharma. What they guide on, and who reported this season.

Most-guided metric families
Revenue
11
Adjusted EPS
6
GAAP EPS
5
Tax rate
5
Buybacks
5
Gross margin
4
Capex
3
Dividends
3
This season’s releases
BioMarin PharmaceuticalAug 6, 202619 changes
Halozyme TherapeuticsAug 6, 20266 changes
Eli LillyAug 5, 20265 changes
AmgenAug 4, 20265 changes
Gilead SciencesAug 4, 202615 changes
ModernaJul 31, 20268 changes
Neurocrine BiosciencesJul 30, 202616 changes
Regeneron PharmaceuticalsJul 30, 202622 changes
Get this for your own peer set — Peer Guidance Briefing, $3,000.

Full history

Every metric, every release, eight quarters — the complete record as one table.

MetricFY2030FY2026FY2025FY2024No period
Diluted (loss) earnings per share————1 statement
Diluted EPS—1 statement2 statements—6 statements
GAAP projected diluted EPS——1 statement——
GAAP projected operating income—2 statements4 statements——
GAAP projected product gross margin—2 statements4 statements——
The full record for Gilead Sciences and its Biopharma peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.

Filings

The 8 earnings releases this page is built from.

FiledFiscal periodAccessionGuidance items
Aug 4, 2026FY2026 Q20000882095-26-00002820Open filing ↗
May 7, 2026FY2026 Q10000882095-26-0000227Open filing ↗
Feb 10, 2026FY2025 Q40000882095-26-00000315Open filing ↗
Oct 30, 2025FY2025 Q30000882095-25-00004420Open filing ↗
Aug 7, 2025FY2025 Q20000882095-25-00003014Open filing ↗
Apr 24, 2025FY2025 Q10000882095-25-00000918Open filing ↗
Feb 11, 2025FY2024 Q40000882095-25-00000316Open filing ↗
Nov 6, 2024FY2024 Q30000882095-24-0000257Open filing ↗
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error